Table 1 Background characteristics of patients who received hepatic arterial infusion chemotherapy

Age (years)

66 (32–88)

Gender (M/F)

49/6

ECOG performance status (0/1)

50/5

Etiology (HBV/HCV/others)

14/24/17

Platelet count (/mm³)

15.6 (6.4–41.4)

Total bilirubin (mg/dL)

0.9 (0.3–1.8)

Albumin (g/dL)

3.7 (2.7–5.0)

Prothrombin consumption test (%)

78 (57.4–118)

Child-Pugh score (5/6/7)

22/23/10

Number of liver tumors

5 (1–40)

Size of liver tumors (mm)

85 (18–170)

Macroscopic vascular invasion (without/with)

17/38

Vp (0–2/3–4)^a

26/29

Vv (0–1/2–3)

46/9

Relative tumor size in the liver (<  50%/≥ 50%)

47/8

TACE refractory (without/with)

42/13

Extrahepatic spread (without/with)

49/6

HCC stage (III/IVa/IVb)^b

30/22/3

BCLC stage (B/C)^c

18/37

AFP (ng/mL)

1895.2 (2.6–529,500)

DCP (mAU/mL)

3854 (24–226,990)